Shareholders to Vote on Significant Equity Plan Share Increases

summarizeSummary

Harvard Bioscience filed its definitive proxy statement, outlining proposals for its annual meeting, including requests to authorize an additional 520,000 shares for its employee stock purchase and incentive plans, representing a potential dilution of over 11% of current outstanding shares.

check_boxKey Events

• Annual Meeting Scheduled

  The company will hold its virtual Annual Meeting of Stockholders on Tuesday, June 2, 2026, to vote on several proposals.

• Proposed Increase in ESPP Shares

  Shareholders will vote on an amendment to increase the number of authorized shares for the Employee Stock Purchase Plan by 120,000 shares.

• Proposed Increase in Incentive Plan Shares

  Shareholders will vote on an amendment to increase the number of authorized shares for the 2021 Incentive Plan by 400,000 shares.

• Significant Potential Dilution

  The combined increase of 520,000 shares represents a potential dilution of approximately 11.53% of the current 4,510,217 outstanding common stock if all authorized shares were issued.

auto_awesomeAnalysis

Harvard Bioscience filed its definitive proxy statement, outlining proposals for its annual meeting on June 2, 2026. Key proposals include seeking shareholder approval to increase the number of shares available for its Employee Stock Purchase Plan (ESPP) by 120,000 shares and its 2021 Incentive Plan by 400,000 shares. If approved, these amendments would authorize the issuance of an additional 520,000 shares, representing a potential dilution of approximately 11.53% based on the current 4,510,217 outstanding shares. While these equity plans are vital for attracting and retaining key talent, especially in light of the company's recent $56.7 million net loss and debt refinancing, the substantial potential dilution could be a concern for existing shareholders. Other routine proposals include the election of two Class II Directors, ratification of the independent auditor, and an advisory vote on executive compensation.